Surgical excision versus clinical follow-up: Outcomes of benign intraductal papillomas diagnosed on core needle biopsy.

Autor: Jin Z; Department of Anatomic and Clinical Pathology, HCA Healthcare, USF Morsani College of Medicine, USA., Al Qaysi N; Department of Pathology, University of California, Davis, USA., Hanna M; Department of Radiology, University of Florida, Gainesville, USA., Moses V; Division of Rheumatology, Department of Medicine, Baylor Scott and White Health, Temple, TX, USA., Spiguel L; Department of Surgery, University of Florida, Gainesville, USA., Shaw C; Department of Surgery, University of Florida, Gainesville, USA., Asirvatham JR; Department of Pathology, Baylor Scott and White Health, Temple, TX, USA. Electronic address: ruth.asirvatham@bswhealth.org.
Jazyk: angličtina
Zdroj: American journal of surgery [Am J Surg] 2024 Jul; Vol. 233, pp. 114-119. Date of Electronic Publication: 2024 Feb 28.
DOI: 10.1016/j.amjsurg.2024.02.039
Abstrakt: Objective: To compare outcomes between benign intraductal papillomas diagnosed on core need biopsy that were excised (BIP-E) versus those that were followed-up (BIP-F) at our institution.
Methods: Patients were identified by an electronic data base search from January 2010 to October 2016. After exclusions, clinical, radiological and histologic variables were evaluated and biopsy and excision slides reviewed.
Results: 110 BIP from 104 females were analyzed. 84 BIP were excised and 26 BIP were followed up (mean 43.3 months, range 7-93 months).11 patients in BIP-E group had atypia on excision. There were no statistically significant differences between BIP-E with atypia and BIP-E without, except for clinical presentation with pain/discomfort (p ​= ​0.015) in the former. There were no true upgrades to malignancy in both groups on follow up. One patient from each group developed a new breast cancer distant from IP site after nearly 4 years of uneventful follow-up.
Conclusion: Clinical follow up is an oncologically safe alternative for radiologically concordant BIP. Excision may be considered if a diagnosis of atypia would impact surveillence and chemoprevention recommendations.
Competing Interests: Declaration of competing interest JRA served as an advisor for and received compensation from Roche. The other authors declare that they have no conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: